In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Epic Sciences closes $52mm Series E round

Executive Summary

Epic Sciences Inc. raised $52mm through its Series E round led by Blue Ox Healthcare Partners. Deerfield Management and Varian also participated, along with existing investors Altos Capital Partners, Genomic Health, Domain Associates, VI Ventures, Alexandria Venture Investments, and Sabby Management. Epic is developing molecular diagnostics for cancer and will use the Series E money to advance development of its predictive tests designed with the company's No Cell Left Behind platform.
Deal Industry
  • Biotechnology
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies

Advertisement
UsernamePublicRestriction

Register